Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-15

Study Completion Date

2019-09-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the metformin drug effect as a drug that found to improve the quality of tissues, decrease signs \& symptoms of cancer, and decrease histo-pathological criteria of dysplasia.

This will be done by the aid of measuring salivary Micro RNA 31 \& 210 in saliva in addition to measure cyclin A2 as an immuno-histochemical analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions

NCT03685409

Oral Cancer

UNKNOWN PHASE3

Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

NCT04387630

Breast Cancer

UNKNOWN PHASE2/PHASE3

Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

NCT03618472

Metformin CA Endometrium

COMPLETED NA

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

NCT05237960

Erythroplakia Oral Leukoplakia

ACTIVE_NOT_RECRUITING PHASE2

Impact Of Metformin In Rectal Cancer Patients

NCT06728982

Rectal Cancer Patients

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oral squamous cell carcinomas (OSCCs) are among the most common types of head and neck cancers and are a major cause of significant morbidity. It was reported that 16- 62% of OSCCs develop from premalignant lesions, which often presents clinically as white or red mucosal patches known as leukoplakia and erythroplakia. The role of miRNA in cancer has been reiterated and established by many studies that have shown that miRNA signatures (i.e., mRNA expression profiles) can be useful for classifying human cancers. These studies have identified "cancer related miRNAs" through investigating expression profiles in matched normal and tumor tissues, as well as in body fluids. In addition, a vast number of studies have shown that miRNAs can play a role in regulating the expression of oncogenes and tumor suppressor genes, whereas others have shown that miRNA gene deletion or mutation can lead cancer initiation, progression and metastasis . Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth in vitro and vivo:

(1) Activation of LKB1/AMPK pathway, (2) Induction of cell cycle arrest and/or apoptosis, (3) Inhibition of protein synthesis, (4) Reduction in circulating insulin levels, (5) Inhibition of the unfolded protein response (UPR), (6) Activation of the immune system.

This study is performed to evaluate metformin effect on the patients premalignant lesion versus maintenace follow ups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized clinical trials

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin Hcl 500Mg 24Hr Sa Tab

Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient

Group Type ACTIVE_COMPARATOR

Metformin Hcl 500Mg 24Hr Sa Tab

Intervention Type DRUG

Glucophage 500 mg once daily

control

starch tablets

Group Type PLACEBO_COMPARATOR

starch tablet

Intervention Type OTHER

starch tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin Hcl 500Mg 24Hr Sa Tab

Glucophage 500 mg once daily

Intervention Type DRUG

starch tablet

starch tablets

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glucophage

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both genders with age range from 20 to 70 years.
* Patients able to return for the follow up visits and can perform oral hygiene measures.
* Clinically diagnosed and histologically confirmed as having oral potentially malignant lesions.
* Patients agreed to sign a written consent after understanding the nature of the study
* Patients have diagnosed oral premalignant lesion/lesions and not yet turned into malignancy (atrophic lichen planus- leukoplakia-erythroplakia - oral submucous fibrosis)

Exclusion Criteria

* \- Diabetic patients (Diabetes Mellitus Type I \& II)
* Patients have cardiovascular, lung, Renal, Liver diseases
* Patients on H2 blocker \& proton pump inhibitors therapy as Ranitidine (affects metformin absorption and clearance)
* Those with allergy or sensitivity to Metformin or Retinoids therapy or having any contraindication for their use.
* Systemic and/or local systemic drug therapy within the last 3 months prior to the start of the study
* Patients on steroidal or Non-steroidal anti-inflammatory drugs (NSAIDs) for at least the last 6 months
* Patients on Antibiotics treatment for at least the last 2 months
* Patients on Retinoid, green tea supplements or another natural products therapy
* Patients with already diagnosed malignant lesion/lesions
* Pregnant or Lactating females
* Vulnerable groups as prisoners, mentally disabled, etc…

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No